Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. - Wikidata - awgldk - TriplyDB

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

http://www.wikidata.org/entity/Q38379925

about

Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Precision medicine in breast cancer: reality or utopia?Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations Fulvestrant in advanced breast cancer: evidence to date and place in therapy.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer.Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer Current and Emerging Applications of Droplet Digital PCR in Oncology.A Cross-Sectional Comparison of Druggable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells, and Cell-Free Circulating DNA in Patients with Metastatic Breast Cancer: The MIRROR Study Protocol.Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients.Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.Inhibitors of cyclin-dependent kinases as cancer therapeutics.Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.Liquid biopsy: unlocking the potentials of cell-free DNA.Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.ESR1 mutations in breast cancer Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.Advances in Precision Medicine: Tailoring Individualized Therapies.Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

P2860

Q28067549-0E5D8D36-3CB3-4D07-BCD9-724EBDF183EB Q28069856-F5904FFB-781B-497C-ACA0-334F30DAAD6F Q33722765-83E58C7F-0A25-422B-B1CF-19B5AB4ABF5E Q33809114-C1FD80D9-1754-413B-A35C-2E749BF23B8C Q33810500-B1BF0D37-26FC-4960-9031-50846D836257 Q33887675-83E440E5-3963-4547-A4CA-ADBB0795CAF7 Q34534031-EBFAD713-492B-40FE-9D3B-838AF6F68FAF Q36179080-D118C512-AF93-49AA-BC0C-F60A2F66345E Q36233893-EE4CEFF7-CD98-40CC-97A3-3203C272C63F Q37319203-ED0C9046-F6BA-461C-B769-948B56B4AAF3 Q37631514-358CA8BB-630D-4B2A-85EB-347CE4ABC545 Q37632170-05283373-AFD5-4537-B22F-A53C206D4777 Q37667038-A451AC71-3640-41CA-BF1B-AC4AD13E11A7 Q37699590-D6FB9125-01A0-45EE-90D2-AF1C39637F4F Q38374623-C9BE9CFB-5D25-4EDA-BD40-40E6FA23E3EA Q38378783-FAA03CEF-67A1-4DAD-A361-B2C2224C2F50 Q38640496-B7E6EB94-0EB7-4FE4-9E36-D5CDC3A536A9 Q38913843-070A6891-7E14-458B-9ADB-96A7F5A35008 Q38933237-4486AC16-9AAD-4105-B09E-7A9186C7B519 Q38934402-AA552CA7-4FCD-461A-8332-0311295D23B6 Q39125016-B231C59B-DA39-4A75-B204-2185DF7CFC6C Q39172983-08839419-FF90-477F-9B25-EA2FAE907A63 Q39186932-C6C75A36-3E94-42C5-9710-A8EBB551360B Q39214999-4EEBA8D6-AA2E-4833-B4B9-50F79C2475DE Q39218132-C2497C94-5FA4-4E50-8EDD-C4187E9E057B Q39227889-3B98A6F5-9601-4F60-B428-3FD0E8EFE45F Q39279845-A0195D9D-6236-4D50-AA93-86C765020A6E Q39294871-5A8A0A0E-4880-4090-A877-0576085A32B6 Q40503471-123D6AFA-FDBA-42F8-8B42-1206F98B249D Q41551635-B67FBE69-AA0F-4E65-A81F-6385520123B3 Q42321343-FF74DB0F-7DC3-426C-A8A4-ABCE1C7D61A9 Q46311036-2C94B26A-08EA-4AA1-847C-2F36CF2911E4 Q46670174-C2D1EBAC-69CF-40D0-89B4-CB3D75E6E61F Q47105247-E1C6FCA8-9EED-4269-8E8A-8416938BA4BD Q47127824-F5FE03DE-F5B9-4F7A-A42F-FE5EF6EEBC7D Q47160721-D920D7B6-5348-473A-B70C-B500EDC587A2 Q47163200-14BC25AC-B106-483A-BE8A-705BEFB238F9 Q47214510-BD648DDF-C5F2-4EB7-AA97-B48D2D269C26 Q47316489-69607C57-3AE9-4775-BD8F-24E6095337E1 Q47321016-81F7ABBF-C364-4807-A04D-24233317B27B

P2860

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

http://www.wikidata.org/entity/Q38379925

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Plasma ESR1 Mutations and the ...... sitive Advanced Breast Cancer.

@en

type

label

Plasma ESR1 Mutations and the ...... sitive Advanced Breast Cancer.

@en

prefLabel

Plasma ESR1 Mutations and the ...... sitive Advanced Breast Cancer.

@en

P1433

Q38379925-E318149F-19DF-4C23-A849-05ACD4A6CD43

P1476

Q38379925-BF6B271D-558C-475C-9182-F147988C5536

P2093

Q38379925-0405B645-0E0C-4433-A9EF-6348698F4BCD

Q38379925-0D1BB7B9-E21C-4DDB-9C68-248E6A2D3A81

Q38379925-28F73F93-0EA6-4A21-A32F-A886D4E6A3A4

Q38379925-3AAADF1A-3238-4ED8-A654-F308813FCCFF

Q38379925-701C1F52-026C-4F0D-9689-11DA684C2CF3

Q38379925-BB73D05A-D905-4964-B15A-114FA8A273B4

Q38379925-CA726068-A8DC-4A77-8121-FDD1DA630FAE

Q38379925-ED5DB969-0F7F-41D0-B143-4DE41DB33914

Q38379925-F1C58111-28F2-450C-9E67-A0D1D573C27E

Q38379925-F2FC1B58-DF19-4638-B7EF-0F57838ABF3A

P304

Q38379925-C7B5246D-7077-4DFE-96DF-8A6DC997A1ED

P31

Q38379925-6800574E-9568-49B5-BAF1-A53B194D4F5A

P356

Q38379925-3C3E7FAC-48F9-4F29-B1C6-DD22131571B5

P407

Q38379925-C962A0A0-41E0-4BAE-AC96-FAFF67A017F9

P433

Q38379925-0003849F-5C7F-4FAB-892C-C8317D89AE61

P478

Q38379925-59988C18-20CC-4DF9-9D66-9261FCB7955B

P50

Q38379925-4FF64FEA-994D-4241-A873-6EB41CD391AE

Q38379925-677CE7BE-C4E7-4479-9354-B7F6E7D0D034

Q38379925-7C9FA70A-52E5-4669-9430-5BB2028367E9

Q38379925-AF3B3F14-37C9-494C-B7A5-E18D230FADF7

Q38379925-C84F9FDC-4991-4D17-8721-9FA0E7734BE3

Q38379925-FB04FDF4-3FBC-4731-BFFC-B338DFE8C22C

P577

Q38379925-B6962008-D589-4560-8C2C-C6C7E1C46F47

P698

Q38379925-1B59D4EF-BBC2-4D6D-A8A5-7722BBC9D4AB

P356

JCO.2016.67.3061

P1433

Journal of Clinical Oncology

P1476

Plasma ESR1 Mutations and the ...... ositive Advanced Breast Cancer

@en

P2093

Cynthia Huang Bartlett

http://www.w3.org/2001/XMLSchema#string

Isaac Garcia-Murillas

http://www.w3.org/2001/XMLSchema#string

John Jiang

http://www.w3.org/2001/XMLSchema#string

Lucy Kilburn

http://www.w3.org/2001/XMLSchema#string

Maria Koehler

http://www.w3.org/2001/XMLSchema#string

Massimo Cristofanilli

http://www.w3.org/2001/XMLSchema#string

Matthew Beaney

http://www.w3.org/2001/XMLSchema#string

Nicholas C Turner

http://www.w3.org/2001/XMLSchema#string

Sarah Hrebien

http://www.w3.org/2001/XMLSchema#string

Sibylle Loibl

http://www.w3.org/2001/XMLSchema#string

P304

2961-2968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2016.67.3061

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27269946

http://www.w3.org/2001/XMLSchema#string